Novo Nordisk Fights Back Dipping Sales In China By Expanding R&D, Manufacturing Capacity
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Diabetes-focused Danish firm Novo Nordisk A/S is not deterred by a dip in China sales, and is planning to expand its R&D center and manufacturing capability in China to maintain its leading position in the country
You may also be interested in...
Diabetes Surge Drives Novo Nordisk To Expand Organically In Emerging Markets As Sanofi Moves To Buy
An expected surge in the number of diabetic patients has prompted the world’s biggest insulin manufacturer to build up resources in emerging markets, most recently unveiling its largest overseas R&D center, while rival Sanofi eyes acquisitions.
Diabetes Surge Drives Novo Nordisk To Expand Organically In Emerging Markets As Sanofi Moves To Buy
An expected surge in the number of diabetic patients has prompted the world’s biggest insulin manufacturer to build up resources in emerging markets, most recently unveiling its largest overseas R&D center, while rival Sanofi eyes acquisitions.
Diabetes Surge Drives Novo Nordisk To Expand Organically In Emerging Markets As Sanofi Moves To Buy
An expected surge in the number of diabetic patients has prompted the world’s biggest insulin manufacturer to build up resources in emerging markets, most recently unveiling its largest overseas R&D center, while rival Sanofi eyes acquisitions.